Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. Erie
    4. ›
  4. 14068
    5. ›
  5. TRANSIRA THERAPEUTICS LLC

TRANSIRA THERAPEUTICS LLC

Company claim

Is this your business?

Get access!

Company Details

Name: TRANSIRA THERAPEUTICS LLC
Jurisdiction: New York
Legal type: DOMESTIC LIMITED LIABILITY COMPANY
Status: Active
Date of registration: 28 Oct 2015 (10 years ago)
Entity Number: 4841376
ZIP code: 14068
County: Erie
Place of Formation: New York
Address: 106 GOLDEN PHEASANT DRIVE, GETZVILLE, NY, United States, 14068

DOS Process Agent

Name Role Address
TRANSIRA THERAPEUTICS LLC DOS Process Agent 106 GOLDEN PHEASANT DRIVE, GETZVILLE, NY, United States, 14068

U.S. Small Business Administration Profile

Phone Number:
716-393-7917
E-mail Address:
qinglinny@gmail.com
Contact Person:
QING LIN
User ID:
P1993826

Unique Entity ID

Unique Entity ID:
M2NZMMLMNGK9
CAGE Code:
7HAG0
UEI Expiration Date:
2026-03-16

Business Information

Activation Date:
2025-03-18
Initial Registration Date:
2015-11-06

Commercial and government entity program

CAGE number:
7HAG0
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2025-03-18
CAGE Expiration:
2030-03-18
SAM Expiration:
2026-03-16

Contact Information

POC:
QING LIN

Filings

Filing Number Date Filed Type Effective Date
191004060105 2019-10-04 BIENNIAL STATEMENT 2019-10-01
171220006049 2017-12-20 BIENNIAL STATEMENT 2017-10-01
160413000085 2016-04-13 CERTIFICATE OF PUBLICATION 2016-04-13
151028010190 2015-10-28 ARTICLES OF ORGANIZATION 2015-10-28

USAspending Awards / Financial Assistance

Date:
2021-09-17
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
DEVELOPMENT OF ORALLY ADMINISTERED PEPTIDE HORMONES FOR TREATMENT OF DIABETES AND OBESITY - ABSTRACT THE RISING OBESITY RATE ACROSS ALL AGE GROUPS UNDERLINES THE DRAMATIC INCREASE IN THE INCIDENCE OF DIABETES IN THE UNITED STATES. ACCORDING TO CDC, 34.2 MILLION PEOPLE OR 10.5% OF U.S. POPULATION HAVE DIABETES IN 2018, WITH AN ESTIMATED TOTAL COST OF $327 BILLION TO THE HEALTHCARE SYSTEM. THE MEDICAL COMMUNITY HAS RECOGNIZED THAT DIABETES TREATMENTS SHOULD IDEALLY LEAD TO BOTH BLOOD GLUCOSE CONTROL AND BODYWEIGHT LOSS. THE MISSION OF TRANSIRA THERAPEUTICS IS TO DEVELOP AN INNOVATIVE BEST-IN-CLASS ORAL PEPTIDE DRUG FOR THE TREATMENT OF THE DIABETES AND OBESITY USING OUR PROPRIETARY PEPTIDE STAPLING CHEMISTRY. THE GOAL OF THIS PROJECT IS TO DEVELOP A CHEMICALLY MODIFIED PEPTIDE DUAL AGONIST OF GIPR/GLP-1R AS A ONCE-DAILY ORAL DRUG FOR THE TREATMENT OF DIABETES AND OBESITY. IN OUR PRELIMINARY STUDIES, WE IDENTIFIED TWO STAPLED PEPTIDES THAT SHOW BIASED DUAL GIP AND GLP-1 RECEPTOR AGONISTS ALONG WITH THE DRASTICALLY IMPROVED PROTEOLYTIC STABILITY AND ROBUST IN VIVO GLUCOSE- LOWERING EFFICACY. IN THIS SBIR PHASE I APPLICATION, WE HAVE TWO SPECIFIC AIMS: (1) SYNTHESIS AND EVALUATION OF THE CHIMERIC GIPR/GLP-1R PEPTIDE DUAL AGONISTS CONTAINING A LIPID-MODIFIED CHEMICAL STAPLER FOR IMPROVED ORAL BIOAVAILABILITY; AND (2) PRECLINICAL ASSESSMENT OF THE PHARMACOKINETICS, GLUCOSE CONTROL, BODYWEIGHT REDUCTION, AND OTHER METABOLIC EFFECTS OF THE ORALLY ADMINISTERED GIPR/GLP-1R PEPTIDE DUAL AGONIST IN DIO MICE. WE EXPECT TO IDENTIFY ONE FATTY DIACID-CONTAINING BIARYL-STAPLED PEPTIDE THAT EXHIBITS PAPP VALUE >100 TIMES GREATER THAN SEMAGLUTIDE (WITH A PERMEATION ENHANCER IF NECESSARY) IN THE CACO-2 CELL MONOLAYER TRANSPORT ASSAY AND GLUCOSE-LOWERING EFFICACY GREATER THAN OR EQUAL TO SEMAGLUTIDE IN ORAL GLUCOSE TOLERANCE TEST (OGTT). ALSO, WE EXPECT THE LIPID-CONTAINING STAPLED PEPTIDE TO SHOW GREATER ORAL BIOAVAILABILITY THAN ORAL SEMAGLUTIDE, >25% DECREASE IN FASTING GLUCOSE LEVELS IN INTRAPERITONEAL GLUCOSE TOLERANCE TEST (IPGTT), AND >20% BODYWEIGHT REDUCTION AFTER PO ADMINISTRATION COMPARED TO PLACEBO IN DIO MICE. THE SUCCESSFUL COMPLETION OF THE PHASE I STUDIES SHOULD LAY A SOLID FOUNDATION FOR THE IND-ENABLING PHASE II STUDIES IN THE FUTURE.
Obligated Amount:
257105.48
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2020-05-03
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
3430.00
Total Face Value Of Loan:
3430.00
Date:
2020-05-03
Link:
View on USAspending
Awarding Agency Name:
Small Business Administration
Transaction Description:
TO AID SMALL BUSINESSES IN MAINTAINING WORK FORCE DURING COVID-19 PANDEMIC.
Obligated Amount:
0.00
Face Value Of Loan:
3430.00
Total Face Value Of Loan:
3430.00
Date:
2018-06-18
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
DEVELOPMENT OF STAPLED OXYNTOMODULIN-FC FUSION PROTEINS FOR THE TREATMENT OF DIABETES AND OBESITY
Obligated Amount:
224000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2018-06-18
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
DEVELOPMENT OF STAPLED OXYNTOMODULIN-FC FUSION PROTEINS FOR THE TREATMENT OF DIABETES AND OBESITY
Obligated Amount:
224000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Paycheck Protection Program

Jobs Reported:
1
Initial Approval Amount:
$3,430
Date Approved:
2020-05-01
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Current Approval Amount:
$3,430
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
$3,455.75
Servicing Lender:
Bank of America, National Association
Use of Proceeds:
Payroll: $3,430

Reviews Leave a review

This company hasn't received any reviews.

Related by officers

No related officers

Related by address

No related companies by address

Date of last update: 25 Mar 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated